Day One Biopharmaceuticals, a Phase 2 biotech developing treatments for pediatric glioma and other cancers, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.
Day One Biopharmaceuticals aims to treat patients of all ages with genetically defined cancers, but is initially focused on pediatric patients, which it believes have been underserved by recent cancer treatment advancements. The company's lead candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor. The company has initiated a pivotal Phase 2 trial for DAY101 for the treatment of pediatric patients with relapsed or progressive low-grade glioma, for which DAY101 has been granted Breakthrough Therapy designation. The company anticipates an initial data readout in the 1H22, and expects to file an NDA in 2023.
The San Francisco, CA-based company was founded in 2018 and plans to list on the Nasdaq under the symbol DAWN. Day One Biopharmaceuticals filed confidentially on March 19, 2021. J.P. Morgan, Cowen, Piper Sandler and Wedbush PacGrow are the joint bookrunners on the deal. No pricing terms were disclosed.
